SNTI Stock Analysis: Buy, Sell, or Hold?
SNTI - Senti Biosciences, Inc. Common Stock
$0.35
0.01 (2.21%)
▲
5d:
-10.07%
30d:
-9.74%
90d:
-64.37%
WAIT
LOW Confidence
Analysis Updated: Sep 2, 2026 12:00 AM ET
Earnings: Aug 20, 2026
0d
Get Alerted When SNTI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: SNTI is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: SNTI is down 10.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: SNTI is currently trading at $0.35, which is considered oversold relative to its 30-day fair value range of $0.35 to $0.41.
Technical Outlook: Technically, SNTI is in a strong downtrend. Immediate support is located at $0.33, while resistance sits at $0.48.
Market Sentiment: SNTI scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.50 (+3870.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SNTI is in a strong downtrend. Immediate support is located at $0.33, while resistance sits at $0.48.
Market Sentiment: SNTI scores 28/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.50 (+3870.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.35 -
$0.41
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (28/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 3870.6% below Wall St target ($13.50)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.35 -
$0.41
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.33
Resistance Level
$0.48
Current Trend
Strong Downtrend
Technical data as of
Sep 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.36
Wall Street Target
$13.50
(+3870.6%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: September 02, 2026 1:55 PM ET
Data refreshes hourly during market hours. Next update: 2:55 PM
Data refreshes hourly during market hours. Next update: 2:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNTI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$200 | 44 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$88 | 44 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$110 | 53 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 41 HOLD |
